OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press21010.17650/1818-8346-2016-11-3-86-89PHARMACOTHERAPYФАРМАКОТЕРАПИЯProteasome inhibitors: situation and prospects (literature review and own data)Препараты класса ингибиторов протеасом: состояние вопроса и перспективы (обзор литературы и собственные данные)RukavitsynA. A.РукавицынА. А.
Russian Federation
rukavitsin46@gmail.comRukavitsynO. A.РукавицынО. А.
Russian Federation
N.N. Burdenko Main Military Clinical Hospital, Ministry of Defense of RussiaФГКУ «Главный военный клинический госпиталь им. акад. Н. Н. Бурденко» Минобороны России1010201611386891010201610102016https://oncohematology.abvpress.ru/ongm/article/view/210

Multiple myeloma is a clonal B-cell malignancy characterized by proliferation of plasma cells that accumulate mainly in bone marrow and usually secrete monoclonal Ig and/or Ig light chains. The history of therapy development in this disease has more than 50 years. After ubiquitin-proteasome system of apoptosis become apparent bortezomib has been included in the mains therapy regimes. Simultaneously, the group of proteasome-inhibitor drugs is continually developing and opening more therapeutic options in refractory or relapse forms.

Множественная миелома – клональное B-клеточное злокачественное новообразование с клональной пролиферацией атипических плазматических клеток в основном в костном мозге, синтезирующих моноклональные иммуноглобулины и/или легкие цепи. Исто-рия развития лекарственной терапии насчитывает более 50 лет. После открытия убиквитинзависимого механизма гибели клетки основные режимы терапии стали включать бортезомиб. В то же время группа препаратов – ингибиторов протеасом непрерывно развивается, тем самым открывая дополнительные терапевтические опции в отношении рецидивирующих/рефрактерных форм.

multiple myelomaproteasome inhibitorsubiquitin-proteasome systemnew treatment of multiple myelomabortezomibcarfilzomibixazomibmarizomibVelcadeBartizarмножественная миеломаингибиторы протеасомубиквитинзависимый протеасомный путьновые перспекти- вы лечения множественной миеломыбортезомибкарфилзомибиксазомибмаризомибВелкейдБартизар1. Рукавицын О. А. Гематология. Национальное руководство. 2015. С. 565–573, 751. [Rukavitsyn O. A. Hematology. National guidelines. 2015. Pp. 565–573, 751. (In Russ.)].Рукавицын О. А. Гематология. Национальное руководство. 2015. С. 565–573, 751. [Rukavitsyn O. A. Hematology. National guidelines. 2015. Pp. 565–573, 751. (In Russ.)].2. Войцеховский В. В., Ландышев Ю. С. Множественная миелома, современные принципы диагностики и лечения. Минздравсоцразвития РФ, ГБОУ ВПО «Амурская государственная медицинская академия», 2012. С. 74–77. [Voytsekhovskiy V. V., Lahdyshev Yu. S. Multiple myeloma, current principles of diagnosis and treatment. Ministry of Health of Russian Federation, Amur State Medical Academy, 2012. Pp. 74–77. (In Russ.)].Войцеховский В. В., Ландышев Ю. С. Множественная миелома, современные принципы диагностики и лечения. Минздравсоцразвития РФ, ГБОУ ВПО «Амурская государственная медицинская академия», 2012. С. 74–77. [Voytsekhovskiy V. V., Lahdyshev Yu. S. Multiple myeloma, current principles of diagnosis and treatment. Ministry of Health of Russian Federation, Amur State Medical Academy, 2012. Pp. 74–77. (In Russ.)].3. Richardson P. G., Sonneveld P., Schuster M. et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110(10):557– 3560. DOI: 10.1182/blood-2006-08-036947.Richardson P. G., Sonneveld P., Schuster M. et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110(10):557– 3560. DOI: 10.1182/blood-2006-08-036947.4. San-Miguel J. F., Richardson P. G., Sonneveld P. et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008;22(4):842–9. DOI: 10.1038/sj.leu.2405087.San-Miguel J. F., Richardson P. G., Sonneveld P. et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008;22(4):842–9. DOI: 10.1038/sj.leu.2405087.5. Richardson P. G., Xie W., Mitsiades C. et al. Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. J Clin Oncol 2009;27(21):3518–25. DOI: 10.1200/JCO.2008.18.3087.Richardson P. G., Xie W., Mitsiades C. et al. Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. J Clin Oncol 2009;27(21):3518–25. DOI: 10.1200/JCO.2008.18.3087.6. Vij R., Siegel D. S., Jagannath S. et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012;158(6):739–48. DOI: 10.1111/j.1365-2141.2012.09232.x.Vij R., Siegel D. S., Jagannath S. et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012;158(6):739–48. DOI: 10.1111/j.1365-2141.2012.09232.x.7. Siegel D., Martin T., Nooka A. et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013;98(11):1753–61. DOI: 10.3324/haematol.2013.089334.Siegel D., Martin T., Nooka A. et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013;98(11):1753–61. DOI: 10.3324/haematol.2013.089334.8. Avet-Loiseau H., Fonseca R., Siegel D. et al. Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma. Blood 2016;128(9):1174–80. DOI: 10.1182/blood-2016-03-707596.Avet-Loiseau H., Fonseca R., Siegel D. et al. Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma. Blood 2016;128(9):1174–80. DOI: 10.1182/blood-2016-03-707596.9. Ludwig H., Greil R., Masszi T. et al. Bortezomib, thalidomide and dexamethasone, with or without cyclo phosphamide, for patients with previously untreated multiple myeloma: 5-year followup. Br J Haematol 2015;171(3):344–54. DOI: 10.1111/bjh.13582.Ludwig H., Greil R., Masszi T. et al. Bortezomib, thalidomide and dexamethasone, with or without cyclo phosphamide, for patients with previously untreated multiple myeloma: 5-year followup. Br J Haematol 2015;171(3):344–54. DOI: 10.1111/bjh.13582.10. Stewart A. K., Rajkumar S. V., Dimopoulos M. A. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372(2):142–52. DOI: 10.1056/NEJMoa1411321.Stewart A. K., Rajkumar S. V., Dimopoulos M. A. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372(2):142–52. DOI: 10.1056/NEJMoa1411321.11. Kumar S. K., LaPlant B., Roy V. et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J 2015;5:e338. DOI: 10.1038/bcj.2015.60.Kumar S. K., LaPlant B., Roy V. et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J 2015;5:e338. DOI: 10.1038/bcj.2015.60.12. Moreau P., Masszi T., Grzasko N., Bahlis N. J. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374(17):1621–34. DOI: 10.1056/NEJMoa1516282.Moreau P., Masszi T., Grzasko N., Bahlis N. J. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374(17):1621–34. DOI: 10.1056/NEJMoa1516282.13. Kumar S. K., Bensinger W. I., Zimmerman T. M. et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 2014;124(7):1047–55. DOI: 10.1182/blood-2014-01-548941.Kumar S. K., Bensinger W. I., Zimmerman T. M. et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 2014;124(7):1047–55. DOI: 10.1182/blood-2014-01-548941.14. Rajan A. M., Kumar S. New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J 2016;6(7):e451. DOI: 10.1038/bcj.2016.53.Rajan A. M., Kumar S. New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J 2016;6(7):e451. DOI: 10.1038/bcj.2016.53.15. Dimopoulos M. A., Beksac M., Benboubker L. et al. Phase II study of bortezomib – dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica 2013;98(8):1264–72. DOI: 10.3324/haematol.2013.084376.Dimopoulos M. A., Beksac M., Benboubker L. et al. Phase II study of bortezomib – dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica 2013;98(8):1264–72. DOI: 10.3324/haematol.2013.084376.